# MR-107A PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mr-107a

> The PDUFA target action date for MR-107A, sponsored by Viatris Inc (VTRS), is December 27, 2026, for moderate-to-severe acute pain. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the MR-107A PDUFA date?

The PDUFA target action date for MR-107A, sponsored by Viatris Inc (VTRS), is December 27, 2026, for moderate-to-severe acute pain. Status: scheduled. Press release filed with the SEC (EX-99): "in May, the Company announced that the FDA accepted for review the New Drug Application for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain and the FDA has assigned a PDUFA goal date of December 27, 2026" Last confirmed August 6, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/mr-107a)

Source: Press release filed with the SEC (EX-99), accession 0001792044-26-000037, https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/exhibit991-2q26earningsrel.htm (retrieved 2026-11-12). Last confirmed 2026-08-06. Cite: https://sec-api.dev/pdufa/mr-107a#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | MR-107A |
| Codes | MR-107A |
| Sponsor | Viatris Inc (VTRS) https://sec-api.dev/companies/vtrs/catalysts |
| Indications | [moderate-to-severe acute pain](https://sec-api.dev/indications/moderate-to-severe-acute-pain) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### late 2025: NDA/BLA submission

- Status: scheduled. Date confidence: half.
- First seen 2025-05-08, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001792044-25-000016): "The Company is targeting to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2025." https://www.sec.gov/Archives/edgar/data/1792044/000179204425000016/exhibit991-1q25earningsrel.htm
- Press release filed with the SEC (EX-99) (accession 0001792044-25-000016): "the Company is targeting to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2025" https://www.sec.gov/Archives/edgar/data/1792044/000179204425000016/exhibit991-1q25earningsrel.htm

### December 27, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: moderate-to-severe acute pain.
- First seen 2026-08-06, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001792044-26-000037): "in May, the Company announced that the FDA accepted for review the New Drug Application for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain and the FDA has assigned a PDUFA goal date of December 27, 2026" https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/exhibit991-2q26earningsrel.htm
- Press release filed with the SEC (EX-99) (accession 0001792044-26-000037): "The FDA has assigned a PDUFA goal date of December 27, 2026." https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/exhibit991-2q26earningsrel.htm

## Same indication

- [Onzotrigine](https://sec-api.dev/pdufa/onzotrigine) (LTGO)
- [JOURNAVX (suzetrigine)](https://sec-api.dev/pdufa/suzetrigine) (VRTX)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mr-107a.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MR-107A PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mr-107a

```bibtex
@misc{secapidev_pdufa_mr_107a_20261116,
  title        = {MR-107A PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mr-107a}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mr_107a_20261116","title":"MR-107A PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mr-107a","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
